Immucell (ICCC) Cash from Operations (2010 - 2025)

Immucell (ICCC) has reported Cash from Operations for 16 consecutive years, with $482541.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Cash from Operations rose 15915.83% year-over-year to $482541.0; the trailing twelve-month figure through Dec 2025 stood at $2.5 million (up 591.61% YoY), and the FY2025 full-year result was $2.5 million, up 591.61% from the prior year.
• Cash from Operations grew to $482541.0 in Q4 2025 per ICCC's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Cash from Operations topped out at $1.6 million in Q2 2025 and bottomed at -$2.8 million in Q1 2023.
• Historically, Cash from Operations has averaged -$121537.1 across 5 years, with a median of $127970.0 in 2021.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 585.75% in 2022, then jumped 15915.83% in 2025.
• Over 5 years, Cash from Operations stood at $587893.0 in 2021, then tumbled by 320.76% to -$1.3 million in 2022, then soared by 44.29% to -$723071.0 in 2023, then surged by 99.58% to -$3051.0 in 2024, then surged by 15915.83% to $482541.0 in 2025.
• According to Business Quant data, Cash from Operations over the past three periods registered $482541.0, -$1.2 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.